Current status of the research on low-level viremia in chronic hepatitis B patients receiving nucleos(t)ide analogues

Fengming LU; Bo FENG; Sujun ZHENG; Suzhen JIANG; Ruifeng YANG; Junliang FU; Dong JI; Shuangsuo DANG; Xiaobo LU; Hongsong CHEN; Xinyue CHEN; Hong REN; Zhiliang GAO; Yuemin NAN; Xiaoyuan XU; Junqi NIU; Wenhong ZHANG; Hui ZHUANG

doi:10.3969/j.issn.1001-5256.2021.06.007

Volume 37 Issue 6

Jun. 2021

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2021 > 37(6): 1268-1274

PDF( 1859 KB)

Current status of the research on low-level viremia in chronic hepatitis B patients receiving nucleos(t)ide analogues

DOI: 10.3969/j.issn.1001-5256.2021.06.007

1.
Department of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University, Beijing 100191, China
2.
Peking University Hepatology Institute, Peking University People's Hospital, Beijing 100044, China
3.
First Department of Liver Disease, Beijing YouAn Hospital, Capital Medical University, Beijing 100069, China
4.
Diagnosis and Treatment Center of Hepatic Fibrosis, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China
5.
Department of Infectious Diseases, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China
6.
Department of Infectious Diseases & Liver Disease Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830000, China
7.
Institute for Viral Hepatitis, Chongqing Medical University, Chongqing 400060, China
8.
Department of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510630, China
9.
Department of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Shijiazhuang 050051, China
10.
Infectious Diseases Center, Peking University First Hospital, Beijing 100034, China
11.
Department of Hepatology, The First Hospital of Jilin University, Changchun 130021, China
12.
Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai 200040, China

Received Date: 2021-05-04
Accepted Date: 2021-05-12
Published Date: 2021-06-20

Abstract

Abstract

Nucleos(t)ide analogues (NAs), which are widely used as the first-line anti-hepatitis B virus (HBV) drugs in clinical practice, can effectively inhibit the replication of HBV DNA, significantly slow down disease progression in chronic hepatitis B (CHB) patients, and reduce the development of end-stage liver diseases such as liver failure and liver cancer. However, for some CHB patients receiving first-line NAs for 48 weeks or longer, serum HBV DNA is still persistently or intermittently higher than the lower detection of limit of sensitive nucleic acid detection reagents. After discussion by the authors, low-level viremia (LLV) is defined as follows: persistent LLV refers to the condition in which CHB patients, who receive entecavir, tenofovir disoproxil fumarate, or tenofovir alafenamide fumarate for ≥48 weeks, have positive for HBV DNA are positive by two consecutive detections with sensitive quantitative PCR, with an interval of 3-6 months, but < 2000 IU/ml; intermittent LLV refers to serum HBV DNA are positive intermittently by at least three consecutive detections, with an interval of 3-6 months, but HBV DNA < 2000 IU/ml. For the diagnosis of LLV, the issues of poor compliance and drug-resistant mutations should be excluded. LLV might be associated with the increased risk of progression to liver fibrosis, or hepatocellular carcinoma in patients with liver cirrhosis under NA treatment, but there are still controversies over whether the original treatment regimen with NAs should be changed after the onset of LLV. This article summarizes the incidence rate of LLV under NA treatment and the influence of LLV on prognosis and analyzes the possible mechanisms of the osnet of LLV, so as to provide a reference for the management of LLV in patients treated with NAs.
- Hepatitis B, Chronic,
- Nucleosides,
- Nucleotides,
- Low-Level Viremia

FullText(HTML)

志谢参与线上研讨及线下讨论的专家(按姓氏拼音顺序)：陈香梅、成军、段钟平、高沿航、韩涛、胡鹏、黄燕、贾继东、江建宁、李军、林炳亮、刘军平、刘燕娜、吕君、王豪、王晖、王磊、魏来、谢青、徐京杭、余祖江、张大志、张缭云、张欣欣、张跃新。此外，本文还经部分中华医学会肝病学分会肝病基础医学与实验诊断协作组成员共同讨论成文。李德瑶、张鹏参与了文献查阅和整理工作。

References(55)

References

[1]	REVILL PA, CHISARI FV, BLOCK JM, et al. A global scientific strategy to cure hepatitis B[J]. Lancet Gastroenterol Hepatol, 2019, 4(7): 545-558. DOI: 10.1016/S2468-1253(19)30119-0.
[2]	Chinese Society of Infectious Disease, Chinese Society of Hepatology, Chinese Medical Association. The expert consensus on clinical cure (functional cure) of chronic hepatitis B[J]. J Clin Hepatol, 2019, 35(8): 1693-1701. DOI: 10.3969/j.issn.1001-5256.2019.08.008. 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎临床治愈(功能性治愈)专家共识[J]. 临床肝胆病杂志, 2019, 35(8): 1693-1701. DOI: 10.3969/j.issn.1001-5256.2019.08.008.
[3]	SARIN SK, KUMAR M, LAU GK, et al. Asian-Pacific Clinical Practice Guidelines on the management of hepatitis B: A 2015 update[J]. Hepatol Int, 2016, 10(1): 1-98. DOI: 10.1007/S12072-015-9675-4.
[4]	European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2): 370-398. DOI: 10.1016/j.jhep.2017.03.021.
[5]	TERRAULT NA, LOK A, McMAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4): 1560-1599. DOI: 10.1002/hep.29800.
[6]	KIM JH, SINN DH, KANG W, et al. Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment[J]. Hepatology, 2017, 66(2): 335-343. DOI: 10.1002/hep.28916.
[7]	YUEN MF, SETO WK, FUNG J, et al. Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: Viral suppression, viral resistance, and clinical safety[J]. Am J Gastroenterol, 2011, 106(7): 1264-1271. DOI: 10.1038/ajg.2011.45.
[8]	LIU LJ, LIU Y, CHEN RJ, et al. Identification of a novel entecavir-resistant mutation rtL180M+A186T+M204V of hepatitis B virus[J]. Med J Chin PLA, 2019, 44(3): 197-202. DOI: 10.11855/j.issn.0577-7402.2019.03.02. 刘璐洁, 刘妍, 陈容娟, 等. 乙型肝炎病毒新型恩替卡韦耐药突变rtL180M+A186T+M204V的鉴定[J]. 解放军医学杂志, 2019, 44(3): 197-202. DOI: 10.11855/j.issn.0577-7402.2019.03.02.
[9]	LIU Y, MILLER MD, KITRINOS KM. HBV clinical isolates expressing adefovir resistance mutations show similar tenofovir susceptibilities across genotypes B, C and D[J]. Liver Int, 2014, 34(7): 1025-1032. DOI: 10.1111/liv.12343.
[10]	LU C, JIA Y, CHEN L, et al. Pharmacokinetics and food interaction of a novel prodrug of tenofovir, tenofovir dipivoxil fumarate, in healthy volunteers[J]. J Clin Pharm Ther, 2013, 38(2): 136-140. DOI: 10.1111/jcpt.12023.
[11]	European Association for The Study of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection[J]. J Hepatol, 2012, 57(1): 167-185. DOI: 10.1016/j.jhep.2012.02.010.
[12]	BUTI M, GANE E, SETO WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: A randomised, double-blind, phase 3, non-inferiority trial[J]. Lancet Gastroenterol Hepatol, 2016, 1(3): 196-206. DOI: 10.1016/S2468-1253(16)30107-8.
[13]	CHAN HL, FUNG S, SETO WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: A randomised, double-blind, phase 3, non-inferiority trial[J]. Lancet Gastroenterol Hepatol, 2016, 1(3): 185-195. DOI: 10.1016/S2468-1253(16)30024-3.
[14]	AGARWAL K, BRUNETTO M, SETO WK, et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection[J]. J Hepatol, 2018, 68(4): 672-681. DOI: 10.1016/j.jhep.2017.11.039.
[15]	LU JH, YANG L, ZHAO ZX, et al. Comparative study of high-sensitivity and conventional fluorescence quantitative PCR in the monitoring of antiviral efficacy in patients with chronic hepatitis B[J]. J Mol Diagn Ther, 2019, 11(5): 361-364. DOI: 10.3969/j.issn.1674-6929.2019.05.005. 卢建华, 杨莉, 赵召霞, 等. 高敏与普通荧光定量PCR技术在慢乙肝患者抗病毒疗效监测中的对比研究[J]. 分子诊断与治疗杂志, 2019, 11(5): 361-364. DOI: 10.3969/j.issn.1674-6929.2019.05.005.
[16]	LEE SB, JEONG J, PARK JH, et al. Low-level viremia and cirrhotic complications in patients with chronic hepatitis B according to adherence to entecavir[J]. Clin Mol Hepatol, 2020, 26(3): 364-375. DOI: 10.3350/cmh.2020.0012.
[17]	SUN Y, WU X, ZHOU J, et al. Persistent low level of hepatitis B virus promotes fibrosis progression during therapy[J]. Clin Gastroenterol Hepatol, 2020, 18(11): 2582-2591. e6. DOI: 10.1016/j.cgh.2020.03.001.
[18]	MAK LY, HUANG Q, WONG DK, et al. Residual HBV DNA and pgrna viraemia is associated with hepatocellular carcinoma in chronic hepatitis B patients on antiviral therapy[J]. J Gastroenterol, 2021, 56(5): 479-488. DOI: 10.1007/s00535-021-01780-5.
[19]	KIM SS, HWANG JC, LIM SG, et al. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: Comparison between compensated and decompensated cirrhosis[J]. Am J Gastroenterol, 2014, 109(8): 1223-1233. DOI: 10.1038/ajg.2014.145.
[20]	SHIN SK, YIM HJ, KIM JH, et al. Partial virological response after 2 years of entecavir therapy increases the risk of hepatocellular carcinoma in patients with hepatitis B virusassociated cirrhosis[J]. Gut Liver, 2021, 15(3): 430-439. DOI: 10.5009/gnl20074.
[21]	LAI CL, WONG D, IP P, et al. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B[J]. J Hepatol, 2017, 66(2): 275-281. DOI: 10.1016/j.jhep.2016.08.022.
[22]	ALLWEISS L, DANDRI M. The role of cccDNA in HBV maintenance[J]. Viruses, 2017, 9(6): 156. DOI: 10.3390/v9060156.
[23]	WANG J, HUANG H, LIU Y, et al. HBV genome and life cycle[J]. Adv Exp Med Biol, 2020, 1179: 17-37. DOI: 10.1007/978-981-13-9151-4_2.
[24]	KAPOOR R, KOTTILIL S. Strategies to eliminate HBV infection[J]. Future Virol, 2014, 9(6): 565-585. DOI: 10.2217/fvl.14.36.
[25]	ZOULIM F. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection[J]. Antiviral Res, 2004, 64(1): 1-15. DOI: 10.1016/j.antiviral.2004.07.003.
[26]	KARAYIANNIS P. Hepatitis B virus: Old, new and future approaches to antiviral treatment[J]. J Antimicrob Chemother, 2003, 51(4): 761-785. DOI: 10.1093/jac/dkg163.
[27]	ZOULIM F. Antiviral therapy of chronic hepatitis B: Can we clear the virus and prevent drug resistance?[J]. Antivir Chem Chemother, 2004, 15(6): 299-305. DOI: 10.1177/095632020401500602.
[28]	KIM KH, KIM ND, SEONG BL. Discovery and development of anti-HBV agents and their resistance[J]. Molecules, 2010, 15(9): 5878-5908. DOI: 10.3390/molecules15095878.
[29]	DELANEY WE 4th, RAY AS, YANG H, et al. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus[J]. Antimicrob Agents Chemother, 2006, 50(7): 2471-2477. DOI: 10.1128/aac.00138-06.
[30]	HUANG D, ZHANG YZ, CHEN XG. Analysis on intracellular nucleoside triphosphate levels in normal and tumor cell lines by high-performance liquid chromatography[J]. J Harbin Univ Comm(Nat Sci Edition), 2002, 18(3): 241-247. DOI: 10.3969/j.issn.1672-0946.2002.03.001. 黄丹, 张亚卓, 陈晓光. 正常细胞及肿瘤细胞内核苷酸库的分析[J]. 哈尔滨商业大学学报(自然科学版), 2002, 18(3): 241-247. DOI: 10.3969/j.issn.1672-0946.2002.03.001.
[31]	YANG J. Entecavir's pharmacodynamic characteristics and anti-hepatitis B virus trials[J]. China Pharm, 2015, 26(8): 1150-1152. DOI: 10.6039/j.issn.1001-0408.2015.08.50. 杨洁. 恩替卡韦的药效学特征及抗乙型肝炎病毒试验荟萃[J]. 中国药房, 2015, 26(8): 1150-1152. DOI: 10.6039/j.issn.1001-0408.2015.08.50.
[32]	HIGASHI-KUWATA N, HAYASHI S, KUMAMOTO H, et al. Identification of a novel long-acting 4'-modified nucleoside reverse transcriptase inhibitor against HBV[J]. J Hepatol, 2021, 74(5): 1075-1086. DOI: 10.1016/j.jhep.2020.12.006.
[33]	BOYD A, LACOMBE K, LAVOCAT F, et al. Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients[J]. J Hepatol, 2016, 65(4): 683-691. DOI: 10.1016/j.jhep.2016.05.014.
[34]	KOUMBI L. Current and future antiviral drug therapies of hepatitis B chronic infection[J]. World J Hepatol, 2015, 7(8): 1030-1040. DOI: 10.4254/wjh.v7.i8.1030.
[35]	LIU Y, LIU H, HU Z, et al. Hepatitis B virus virions produced under nucleos(t)ide analogue treatment are mainly not infectious because of irreversible DNA chain termination[J]. Hepatology, 2020, 71(2): 463-476. DOI: 10.1002/hep.30844.
[36]	GOYAL A, RIBEIRO RM, PERELSON AS. The role of infected cell proliferation in the clearance of acute HBV infection in humans[J]. Viruses, 2017, 9(11): 350. DOI: 10.3390/v9110350.
[37]	ALLWEISS L, VOLZ T, GIERSCH K, et al. Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo[J]. Gut, 2018, 67(3): 542-552. DOI: 10.1136/gutjnl-2016-312162.
[38]	WONG D, LITTLEJOHN M, EDWARDS R, et al. ALT flares during nucleotide analogue therapy are associated with HBsAg loss in genotype A HBeAg-positive chronic hepatitis B[J]. Liver Int, 2018, 38(10): 1760-1769. DOI: 10.1111/liv.13716.
[39]	YAN Y, ALLWEISS L, YANG D, et al. Down-regulation of cell membrane localized NTCP expression in proliferating hepatocytes prevents hepatitis B virus infection[J]. Emerg Microbes Infect, 2019, 8(1): 879-894. DOI: 10.1080/22221751.2019.1625728.
[40]	GUAN G, ZHENG L, XI J, et al. Cell cycle arrest protein CDKN2C is not an hbv host factor[J]. Virol Sin, 2021. DOI: 10.1007/s12250-020-00337-9.
[41]	YANG RF, CHEN HS, LU FM. New requirements for hepatitis b virus nucleic acid testing in current clinical practice of chronic hepatitis b treatment[J]. Chin J New Clin Med, 2021, 14(1): 1-7. DOI: 10.3969/j.issn.1674-3806.2021.01.01. 杨瑞锋, 陈红松, 鲁凤民. 当今慢性乙型肝炎治疗实践对HBV核酸检测方法的新需求[J]. 中国临床新医学, 2021, 14(1): 1-7. DOI: 10.3969/j.issn.1674-3806.2021.01.01.
[42]	TERRAULT NA, BZOWEJ NH, CHANG KM, et al. AASLD guidelines for treatment of chronic hepatitis B[J]. Hepatology, 2016, 63(1): 261-283. DOI: 10.1002/hep.28156.
[43]	TENNEY DJ, ROSE RE, BALDICK CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy[J]. Hepatology, 2009, 49(5): 1503-1514. DOI: 10.1002/hep.22841.
[44]	ZOUTENDIJK R, REIJNDERS JG, BROWN A, et al. Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response[J]. Hepatology, 2011, 54(2): 443-451. DOI: 10.1002/hep.24406.
[45]	CHO JY, SOHN W, SINN DH, et al. Long-term real-world entecavir therapy in treatment-naïve hepatitis B patients: Base-line hepatitis B virus DNA and hepatitis B surface antigen levels predict virologic response[J]. Korean J Intern Med, 2017, 32(4): 636-646. DOI: 10.3904/kjim.2016.096.
[46]	YIM HJ, KIM IH, SUH SJ, et al. Switching to tenofovir vs continuing entecavir for hepatitis B virus with partial virologic response to entecavir: A randomized controlled trial[J]. J Viral Hepat, 2018, 25(11): 1321-1330. DOI: 10.1111/jvh.12934.
[47]	CHEN J, ZHAO SS, LIU XX, et al. Comparison of the efficacy of tenofovir versus tenofovir plus entecavir in the treatment of chronic hepatitis B in patients with poor efficacy of entecavir: A systematic review and meta-analysis[J]. Clin ther, 2017, 39(9): 1870-1880. DOI: 10.1016/j.clinthera.2017.07.015.
[48]	WANG YH, LIAO J, ZHANG DM, et al. Tenofovir monotherapy versus tenofovir plus entecavir combination therapy in HBeAg-positive chronic hepatitis patients with partial virological response to entecavir[J]. J Med Virol, 2020, 92(3): 302-308. DOI: 10.1002/jmv.25608.
[49]	CHAUNG KT, O'BRIEN C, HA NB, et al. Alternative therapies for chronic hepatitis B patients with partial virological response to standard entecavir monotherapy[J]. J Clin Gastroenterol, 2016, 50(4): 338-344. DOI: 10.1097/mcg.0000000000000455.
[50]	LI ZB, LI L, NIU XX, et al. Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia[J]. Liver Int, 2021. DOI: 10.1111/liv.14786.[Onlineaheadofprint]
[51]	HU P, SHANG J, ZHANG WH, et al. HBsAg loss with Pegylated-interferon alfa-2a in hepatitis B patients with partial response to nucleos(t)ide analog: New switch study[J]. Chin J Hepatol, 2018, 26(10): 756-764. DOI: 10.3760/cma.j.issn.1007-3418.2018.10.005. 胡鹏, 尚佳, 张文宏, 等. 核苷(酸)类似物治疗部分应答的乙型肝炎患者通过聚乙二醇干扰素α-2a治疗获得HBsAg消失: New Switch研究[J]. 中华肝脏病杂志, 2018, 26(10): 756-764. DOI: 10.3760/cma.j.issn.1007-3418.2018.10.005.
[52]	YEH ML, HUANG JF, YU ML, et al. Hepatitis B infection: Progress in identifying patients most likely to respond to peginterferon alfa[J]. Expert Rev Gastroenterol Hepatol, 2021, 15(4): 427-435. DOI: 10.1080/17474124.2021.1866985.
[53]	NING Q, HAN M, SUN Y, et al. Switching from entecavir to pegifn alfa-2a in patients with HBeAg-positive chronic hepatitis B: A randomised open-label trial (OSST trial)[J]. J Hepatol, 2014, 61(4): 777-784. DOI: 10.1016/j.jhep.2014.05.044.
[54]	HAN M, JIANG J, HOU J, et al. Sustained immune control in HBeAg-positive patients who switched from entecavir therapy to pegylated interferon-α2a: 1 year follow-up of the OSST study[J]. Antivir Ther, 2016, 21(4): 337-344. DOI: 10.3851/imp3019.
[55]	JIN Y, HUANG CY, WEI FL, et al. Combination therapy in HBeAg-positive chronic hepatitis B patients with poor virological response/HBV resistance to NAs[J]. Infect Dis Info, 2015, 28(5): 273-278. DOI: 10.3969/j.issn.1007-8134.2015.05.005. 金怡, 黄春洋, 魏飞力, 等. 联合治疗策略在应答不佳/耐药HBeAg阳性慢性乙型肝炎患者中的临床研究[J]. 传染病信息, 2015, 28(5): 273-278. DOI: 10.3969/j.issn.1007-8134.2015.05.005.

Relative Articles

Supplements(0)

Cited By

Cited by

Periodical cited type(58)

1.	高娜，高志良. 慢性乙型肝炎功能性治愈离完全治愈还有多远？. 临床肝胆病杂志. 2025(01): 15-23 . 本站查看
2.	吴迎凤，朱树华，周洁. 艾米替诺福韦联合聚乙二醇干扰素治疗慢性乙型肝炎低病毒血症患者疗效. 中华保健医学杂志. 2025(01): 85-88 .
3.	丁丽，陈俏丽，田鹏飞，张旭强，雷志萍. 甘肃地区乙型肝炎病毒分型和耐药突变分析. 检验医学与临床. 2024(01): 24-27 .
4.	贺潇瑾，周娟，龙云铸，李丹，欧阳静，袁婷，卿玲，谭英征. 多交叉置换扩增联合纳米生物传感器技术对低病毒载量慢性乙型肝炎人群快速诊断价值. 临床军医杂志. 2024(02): 169-172 .
5.	石文静，彭杰，张涛，伍玉南，陈斌. 鳖龙软肝片联合抗病毒药治疗乙型肝炎肝硬化的回顾性临床研究. 湖南中医药大学学报. 2024(03): 473-478 .
6.	张祥运，马序竹，于国英. 慢性乙型肝炎患者低病毒血症影响因素及管理策略研究. 肝脏. 2024(02): 247-250 .
7.	邱功钦，谢丹，陈姿任，欧阳石. 高敏PCR在HBV极低病毒载量的慢性乙型肝炎患者中检测的临床意义. 临床肝胆病杂志. 2024(03): 483-488 . 本站查看
8.	高兴雪，李俊峰. 实现慢性乙型肝炎临床治愈的治疗策略. 兰州大学学报(医学版). 2024(02): 66-72 .
9.	徐翔，倪佳丽，秦旨文，郑齐，吴佳俊，马雯娜，盛国平. 基于肝脏病理的慢性乙型肝炎患者危险因素分析及抗病毒治疗适应证探讨. 浙江医学. 2024(09): 908-912+919 .
10.	郑嵘炅，鲁晓擘. 一线核苷（酸）类似物经治的慢性乙型肝炎患者低病毒血症的发生及治疗策略. 临床肝胆病杂志. 2024(05): 880-883 . 本站查看
11.	王娇娇，蔡大川. 慢性乙型肝炎患者低病毒血症的研究现状及挑战. 诊断学理论与实践. 2024(01): 23-29 .
12.	陶学萍，李丽娇，漆阳红，邓勇，欧书强. 慢性乙型肝炎低病毒血症患者转阴的影响因素与治疗策略探讨. 中国医学创新. 2024(15): 162-166 .
13.	王福生，朱世殊，张敏，王建设，李双杰，福军亮，李元元，郭玉明，李静，许红梅，欧阳文献，南月敏，舒赛男，党双锁，徐小元，李太生，侯金林. 儿童慢性乙型肝炎防治专家共识. 传染病信息. 2024(02): 97-112 .
14.	薛李娜，诸国兵，吴琳霖，杨小星. TAF治疗ETV经治的低病毒血症慢性乙型肝炎患者疗效研究. 实用肝脏病杂志. 2024(04): 519-522 .
15.	谢露，刘亚楠，刘光伟，李鹏宇，胡新宁，康秋佳，郭会军. 经治慢性乙型肝炎患者低病毒血症发生率和影响因素的Meta分析. 临床肝胆病杂志. 2024(07): 1334-1342 . 本站查看
16.	中华医学会感染病学分会，中华医学会肝病学分会，中华医学会儿科学分会感染学组，国家感染性疾病临床医学研究中心. 儿童慢性乙型肝炎防治专家共识. 中华肝脏病杂志. 2024(05): 435-448 .
17.	刘新，杜欣雨，鲁凤民. 慢性乙型肝炎患者长期核苷(酸)类似物治疗后仍然发生肝癌的原因探讨. 中华肝脏病杂志. 2024(11): 1032-1036 .
18.	张沙沙，赵迎春，周红霞. 恩替卡韦经治乙肝肝硬化患者低病毒血症对肝癌发病的影响. 临床荟萃. 2024(11): 980-983 .
19.	郑昌荣，黄晓丽. 聚乙二醇干扰素联合富马酸丙酚替诺福韦治疗慢性乙型肝炎的疗效. 肝脏. 2024(11): 1378-1381 .
20.	丁秋雅，和振坤. 一波三折：慢性乙型肝炎适时调整用药方案实现临床治愈1例. 中华肝脏病杂志. 2024(S1): 41-43 .
21.	何单霞，马胜利. 艾米替诺福韦联合聚乙二醇干扰素α-2b治疗慢性乙型肝炎低病毒血症1例. 中华肝脏病杂志. 2024(S1): 37-40 .
22.	崔承杰，崔静，臧淑娴，付娜. 艾米替诺福韦治疗慢性乙型肝炎低病毒血症患者1例. 中华肝脏病杂志. 2024(S1): 44-46 .
23.	韩静，顾鹏，辛永宁，陈立震，毕研贞. 艾米替诺福韦治疗持续性低病毒血症患者1例. 中华肝脏病杂志. 2024(S1): 68-69 .
24.	刘智泓，梁携儿，侯金林. 关于《扩大慢性乙型肝炎抗病毒治疗的专家意见》的几点思考. 临床肝胆病杂志. 2023(01): 14-21 . 本站查看
25.	宋玉文，沙丽丽，陈立震，李梦昆，王玉荣，辛永宁. 富马酸丙酚替诺福韦治疗特殊慢性乙型肝炎的相关进展. 临床肝胆病杂志. 2023(01): 156-161 . 本站查看
26.	封波，郑佳睿，王资隆. 高灵敏乙型肝炎病毒表面抗原和DNA检测的临床应用价值. 中华检验医学杂志. 2023(01): 7-11 .
27.	张群，解曼，田秋菊，柳国芳，张蓓，蔡金贞，饶伟. 乙肝肝移植受者低病毒血症的单中心初步研究. 实用器官移植电子杂志. 2023(01): 33-39 .
28.	肖丽，王欣茹，咸建春. 基于HBV DNA与ALT治疗阈值下调可能难以达到降低HBV相关终末期肝病发生的目的. 肝脏. 2023(02): 155-156+161 .
29.	中华医学会肝病学分会，中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版). 中华传染病杂志. 2023(01): 3-28 .
30.	李彤，孔银，刘元元，刘天府，麻爱娣，李龙泉，裴志燕，张岭漪. 经治慢性乙型肝炎低病毒血症患者人群特征及其相关影响因素：一项单中心横断面回顾性研究. 中华肝脏病杂志. 2023(01): 42-48 .
31.	黄永栩，陈超，保紫红，周小辉. 恩替卡韦治疗的慢性乙型肝炎患者低病毒血症的影响因素. 肝脏. 2023(03): 320-324 .
32.	尤红，王福生，李太生，孙亚朦，徐小元，贾继东，南月敏，王贵强，侯金林，魏来，段钟平，庄辉. 慢性乙型肝炎防治指南(2022年版). 实用肝脏病杂志. 2023(03): 457-478 .
33.	严梅梅，孙丽华. 自然状态下乙型肝炎病毒慢性感染中的低病毒血症. 中华肝脏病杂志. 2023(03): 322-326 .
34.	盛秋菊，韩超，李艳伟，张翀，窦晓光，丁洋. 艾米替诺福韦治疗HBeAg阳性高病毒血症慢性乙型肝炎口服一线核苷(酸)类似物经治不完全应答患者的临床疗效分析. 中华肝脏病杂志. 2023(03): 252-257 .
35.	刘智泓，郝新，侯金林. Treat-all：部分应答和低病毒血症的挑战. 中华肝脏病杂志. 2023(03): 242-246 .
36.	郭丽颖，李晓燕，苏瑞，曹宇，王静，雷金艳，李澎，任玮，宋涛涛，贾建伟，赵洁，伍喜良，苗静. 治疗后慢性乙型肝炎病毒感染者中低病毒血症人群外周血淋巴细胞状态分析. 中华微生物学和免疫学杂志. 2023(07): 525-533 .
37.	吕承秀，陈梅，王纪传，李庆，张琨婷，孙晓琳. 慢性乙型肝炎患者接受核苷（酸）类似物治疗后发生低病毒血症的危险因素及机制研究. 现代检验医学杂志. 2023(05): 133-137+184 .
38.	陶学萍，李丽娇，漆阳红，欧书强，邓勇，李根，邱艳. 提高HBV DNA灵敏度检测对慢性乙型肝炎低病毒血症的临床价值. 中国医药指南. 2023(33): 1-4 .
39.	肖丽，彭海林，王蔚，薛荣荣，官正喜，咸建春. 高灵敏HBV DNA试剂定量下限与检测下限误用可能影响慢性HBV感染的正确诊疗. 肝脏. 2023(11): 1271-1274 .
40.	冯雨薇，戴丹，刘黎明，张建军. 不同抗病毒策略治疗慢性乙型肝炎低病毒血症临床疗效的Meta分析. 现代医学. 2023(12): 1661-1667 .
41.	陈青林. 探讨高病毒载量HBeAg阳性慢性乙型肝炎患者应用替诺福韦和恩替卡韦治疗效果研究. 中国社区医师. 2022(01): 15-17 .
42.	中华医学会肝病学分会. 扩大慢性乙型肝炎抗病毒治疗的专家意见. 中华肝脏病杂志. 2022(02): 131-136 .
43.	樊正勤，曹灵芝，李文颖. 扬州地区67例慢性乙型肝炎低病毒血症患者临床特征分析. 临床医药实践. 2022(04): 265-267 .
44.	盛梦娇，刘敏，张玉亭，耿嘉蔚. 慢性乙型肝炎低病毒血症相关研究进展. 中国感染与化疗杂志. 2022(04): 501-503 .
45.	鲁凤民，黄鸿鑫，毛天皓，陈香梅，庄辉. 衣壳组装调节剂联合核苷(酸)类似物治疗慢性乙型肝炎临床试验中亟待解决的科学问题. 临床肝胆病杂志. 2022(08): 1705-1709 . 本站查看
46.	武甜甜，张翔. HBV基因型的研究现状与发展趋势探讨. 传染病信息. 2022(04): 366-371 .
47.	王辉. 恩替卡韦与替诺福韦酯治疗高病毒载量慢性乙型肝炎患者的临床效果分析. 系统医学. 2022(16): 100-103+132 .
48.	王玉珊，孔银，刘元元，刘天府，麻爱娣，张亚萍，李永芳，张岭漪. 不同转换治疗策略对经治的低病毒血症慢性乙型肝炎患者疗效的影响：单中心回顾性研究. 实用肝脏病杂志. 2022(05): 633-636 .
49.	解洪银，鲁晓岚. 恩替卡韦经治慢性乙肝患者低病毒血症的临床研究进展. 复旦学报(医学版). 2022(05): 777-782 .
50.	鲁瑞，党双锁，刘怡欣，王怡恺，刘晨瑞，李亚萍，吴凤萍，李梅. 富马酸替诺福韦酯治疗的慢性乙型肝炎患者3年血清HBV DNA和HBsAg的动态变化. 临床肝胆病杂志. 2022(10): 2224-2229 . 本站查看
51.	宣碧碧，徐永红，杜忠彩，刘玉，杨玉玲，边城. 慢性乙型肝炎和乙型肝炎肝硬化患者发生低病毒血症的影响因素及其与肝脏炎症、肝纤维化进展的关系o-展. 临床肝胆病杂志. 2022(10): 2252-2259 . 本站查看
52.	程齐齐，杨丽霞，蔡天盼，王亮，孙俊，梁佳圆，刘丽萍，甘厦，阮宁杭，葛善飞. 核苷（酸）类似物初治的慢性乙型肝炎患者发生低病毒血症的影响因素及其动态变化分析. 临床肝胆病杂志. 2022(12): 2716-2722 . 本站查看
53.	中华医学会肝病学分会，中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版). 中华肝脏病杂志. 2022(12): 1309-1331 .
54.	中华医学会肝病学分会，中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版). 中华肝脏病杂志. 2022(12): 1309-1331 .
55.	中华医学会肝病学分会，中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版). 中华临床感染病杂志. 2022(06): 401-427 .
56.	邓亚，张珊，纪冬. 慢性乙型肝炎低水平病毒血症的研究进展. 传染病信息. 2021(04): 342-346 .
57.	韩宁，严丽波，唐红. 慢性乙型肝炎治疗过程中低病毒血症的临床意义和管理策略. 中华肝脏病杂志. 2021(12): 1139-1143 .
58.	王雷婕，顾智强，许梓萌，陈香梅，鲁凤民. 核苷(酸)类药物经治慢性乙型肝炎患者低病毒血症发生的可能机制. 中华肝脏病杂志. 2021(12): 1151-1155 .

Other cited types(22)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2289) PDF downloads(473)

Current status of the research on low-level viremia in chronic hepatitis B patients receiving nucleos(t)ide analogues

DOI: 10.3969/j.issn.1001-5256.2021.06.007